Woodmont Investment Counsel LLC Buys 22,293 Shares of Harrow, Inc. (NASDAQ:HROW)

Woodmont Investment Counsel LLC increased its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 27.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 103,693 shares of the company's stock after buying an additional 22,293 shares during the period. Woodmont Investment Counsel LLC owned 0.29% of Harrow worth $2,758,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Harrow by 89.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company's stock worth $2,078,000 after buying an additional 29,262 shares during the period. GAMMA Investing LLC increased its position in Harrow by 2,401.2% during the first quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock worth $1,670,000 after acquiring an additional 6,027 shares during the period. Northern Trust Corp raised its stake in Harrow by 7.5% during the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company's stock valued at $10,705,000 after purchasing an additional 22,266 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after purchasing an additional 1,462 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Harrow by 8.4% in the 4th quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company's stock valued at $2,900,000 after purchasing an additional 6,690 shares during the period. 72.76% of the stock is currently owned by institutional investors.

Harrow Stock Performance

Harrow stock opened at $30.66 on Friday. Harrow, Inc. has a 52-week low of $19.97 and a 52-week high of $59.23. The company has a debt-to-equity ratio of 2.01, a current ratio of 0.91 and a quick ratio of 0.85. The stock has a fifty day moving average price of $26.88 and a two-hundred day moving average price of $29.32. The firm has a market capitalization of $1.12 billion, a P/E ratio of -54.75 and a beta of 0.40.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). The firm had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. As a group, analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. B. Riley dropped their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. William Blair initiated coverage on Harrow in a report on Tuesday, June 10th. They issued an "outperform" rating for the company. HC Wainwright raised their price objective on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. Finally, BTIG Research assumed coverage on Harrow in a research report on Thursday, June 12th. They set a "buy" rating and a $62.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $61.40.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.